Acta Oncologica最新文献

{"title":"Continuous intrathecal therapy for refractory cancer pain: A systematic review and meta-analysis focusing on partially implanted devices.","authors":"Mohammadhossein Radafshar, Maria Schelin, Elisabeth Bondesson, Sofia Löfvendahl, Eric Ahl, Sven Oredsson, Mikael Segerlantz","doi":"10.2340/1651-226X.2026.45778","DOIUrl":"10.2340/1651-226X.2026.45778","url":null,"abstract":"<p><strong>Context: </strong>Conventional pain therapies sometimes fail in patients with severe neuropathic pain or bone metastases. Intrathecal therapy provides an alternative but is resource-intensive, technically demanding and costly.</p><p><strong>Objective: </strong>To compare the advantages and limitations of partially implanted devices (PIDs) versus conventional medical management or totally implanted devices (TIDs) in adults with cancer-related pain.</p><p><strong>Methods: </strong>A systematic literature review up to September 2024 was conducted, with an updated search performed in August 2026. Eligible studies included those on adults with refractory cancer pain receiving PID intrathecal therapy compared with conventional therapy, and comparative studies evaluating PIDs versus TIDs. Pain intensity was analysed using a meta-analysis; a synthesis without meta-analysis was used for other outcomes.</p><p><strong>Results: </strong>Of the 1,102 records, 15 were included, evaluating pain intensity, systemic opioid dose, quality of life (QoL), depression/anxiety, functional capacity and complications in PID-treated patients. A meta-analysis of pain intensity at 4 weeks showed statistically significant reduction with intrathecal therapy, which also reduced opioid use and improved QoL. Complication rates were lower than in conventional therapy. Investigations of depression/anxiety and functional capacity were limited, with inconsistent findings. Certainty of evidence was moderate for pain intensity and QoL; low for opioid dose, depression/anxiety and complications; and very low for functional capacity.</p><p><strong>Conclusions: </strong>Intrathecal therapy for refractory cancer pain with PIDs provides superior pain relief and improved QoL compared with the conventional therapy in patients with refractory cancer pain. Evidence for psychological and functional outcomes remains limited. Overall certainty of evidence is low to moderate, but findings support intrathecal therapy as a clinically meaningful option for selected patients.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"845-856"},"PeriodicalIF":2.7,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13670362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-mutation patterns and survival associations in lung cancer: a comparative analysis of Swedish and global cohorts.","authors":"Nicholas Karlowatz, Linda Köhn, Cedric Patthey, Jonas Nilsson, Mikael Johansson","doi":"10.2340/1651-226X.2026.46330","DOIUrl":"10.2340/1651-226X.2026.46330","url":null,"abstract":"<p><strong>Background and purpose: </strong>Co-occurring mutations in lung cancer can influence disease progression and treatment response. Understanding these patterns may refine prognostic stratification and therapeutic decisions.</p><p><strong>Patients/materials and methods: </strong>We analysed targeted sequencing data from 528 North Swedish non-small cell lung cancer (NSCLC) patients, validating findings in 2,239 global patients. Co-mutation enrichment was assessed using the Fisher's exact test with odds ratios, and survival associations were evaluated using Kaplan-Meier/log-rank analyses and Cox models.</p><p><strong>Results: </strong>The North Sweden cohort showed non-random co-mutation patterns shaped by pathway dependencies. The combination of Kirsten rat sarcoma virus oncogene homolog (KRAS) and STK11 co-mutation was significantly enriched in both North Sweden (p = 4.7 × 10-4) and globally (p = 2.5 × 10-22), with North Sweden co-mutants showing significantly worse survival compared with KRAS-only cases (p = 0.037). Epidermal growth factor receptor (EGFR)+phosphate and tensin homolog (PTEN) co-mutation was significantly associated with poorer survival in both cohorts (North Sweden: p = 0.013; World: p = 0.0013). EGFR+TP53 co-mutation trended towards poorer survival compared with EGFR alone, reaching significance globally (p = 1.4 × 10-5). Adenomatous polyposis coli (APC) and PTEN were positively enriched in North Sweden (p = 0.018), and co-mutants had worse survival than APC-only cases (p = 0.029), a pattern mirrored globally. KRAS+TP53 was a frequent co-mutation but not prognostically significant. KRAS and EGFR were strongly mutually exclusive in both cohorts.</p><p><strong>Interpretation: </strong>Pathway-level co-mutation interactions, rather than individual mutation burden, drive survival heterogeneity in lung cancer. Specific co-mutations, such as KRAS+STK11 and APC+PTEN, are enriched and linked to worse survival, supporting the clinical relevance of co-mutation analysis in NSCLC.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"836-844"},"PeriodicalIF":2.7,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13660355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tools for providing information to patients about high-tech medical resources for treatment of cancer.","authors":"Julie Gehl, Tatiana Michel, Erik Rokkones, Soleakhena Ken, Gregor Sersa, Irene Torres-Espallardo, Ester Orlandi, Laura Ridolfi, Nina Schmidt, Ingrid Kruecken, Barbara Leonardi, Margareta Haag, Aurélie Garcin, Anne-Laure Giraudet, Sandrine Lavallé, Colin Patrick Cantwell, Alexander Jorge Cortez, Chiara Marazzi, Roger Olofsson Bagge, Massimiliano Petrini, Francesca Bonifazi, Vincent Bourbonne, Frédéric Courbon, Ibrahim Edhemović, Lisa Licitra, Sergio Roman-Roman, Jean-Yves Blay","doi":"10.2340/1651-226X.2026.45529","DOIUrl":"https://doi.org/10.2340/1651-226X.2026.45529","url":null,"abstract":"<p><strong>Background and purpose: </strong>High-tech medical resources play an increasingly important role in cancer diagnosis and treatment. However, accessing information about these technologies remains challenging due to their complexity and a lack of clear information pathways to obtain reliable information. This, in turn, contributes to inequalities in healthcare. Patient/material and methods: The Joint Action Network of Expertise on Cancer (JANE-2) is one of the largest networks under Europe's Beating Cancer Plan. In JANE-2, the work package on High-Tech Medical Resources comprises seven domains of rapidly evolving technologies, namely Nuclear Medicine, Radiomics, Innovative Radiotherapy, Innovative Surgery, Physical Methods of Ablation, Cell Therapies, and Ex-vivo Testing of Agents. Leaders from these domains, together with patient representatives, have authored a review of the challenges of providing patients with information about high-tech medical resources, and have proposed potential solutions.</p><p><strong>Results: </strong>This article describes the challenges associated with providing adequate information to patients, the resulting consequences, and potential solutions. The article also specifically describes technologies related to the seven high-tech domains that are central to cancer treatment. Patient information tools related to these technologies are provided as supplementary material to the article.</p><p><strong>Interpretation: </strong>Cancer diagnosis and treatment are not only becoming increasingly effective but also more complex with the adoption of novel technologies. This article discusses the challenges and potential solutions related to the availability of patient information and provides examples of patient information tools for seven key and rapidly advancing technologies.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"818-835"},"PeriodicalIF":2.7,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted ALK inhibition achieving tumour control in metastatic melanoma: a case report.","authors":"Cornelia Schuster, Irja Alida Oppedal, Liv Iren Vinnem, Eirin Lunden Abrahamsson, Torill Myklestad Barrett, Eli Sihn Samdal Steinskog, Hege Elisabeth Giercksky Russnes, Åslaug Helland","doi":"10.2340/1651-226X.2026.46424","DOIUrl":"https://doi.org/10.2340/1651-226X.2026.46424","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"814-817"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary treatment and relative survival by stage and age in vaginal carcinoma: a population-based SweGCG study.","authors":"Kristina Hellman, Maria Bjurberg, Christer Borgfeldt, Pernilla Dahm Kähler, Angelique Flöter Rådestad, Jenny-Maria Jönsson, Preben Kjølhede, Cecilia Olsson, Camilla Sköld, Katja Stenström Bohlin, Karin Stålberg, Erik Holmberg, Elisabeth Åvall Lundqvist","doi":"10.2340/1651-226X.2026.45598","DOIUrl":"10.2340/1651-226X.2026.45598","url":null,"abstract":"<p><strong>Background and purpose: </strong>This study aimed to investigate treatment patterns and survival outcomes in population-based data describing treatment and survival of primary vaginal carcinoma (VC) in a routine clinical setting, stratified by age group and stage.</p><p><strong>Methods: </strong>This nationwide, population-based study included women diagnosed with epithelial VC between 2011 and 2020, registered in the Swedish Quality Register for Gynecologic Cancer. Five-year relative survival (RS) was estimated using the Pohar Perme method. The excess mortality rate ratio (EMRR) was assessed by Poisson regression.</p><p><strong>Results: </strong>In total, 252 women were identified, 29% were aged ≥ 80 years. The median follow-up time was 7.5 years. The most common stages were I and II (26% each). Definitive radiotherapy, with or without chemotherapy, was administered to 59% of patients. Among women with stage I, 48% underwent primary surgery and 29% received adjuvant radiotherapy. Treatment patterns differed across age groups. Among women aged ≥ 80 years, staging was omitted in 18%, and in stage I disease 25% received palliative therapy. None of the irradiated women aged ≥ 80 years received chemoradiotherapy, compared to all women aged 20-59 years. The overall 5-year RS for stages I-IV was 51% (95% confidence interval [CI] 43-58). In stages I-II, the 5-year RS was 28% among women aged ≥80 years and 84% among those aged < 60 years (EMRR of 5.2; 95% CI 1.7-15.6).</p><p><strong>Interpretation: </strong>Primary treatment of vaginal cancer in Sweden generally followed international guidelines, except among women aged ≥ 80 years. The markedly poorer RS in this age group suggests both diagnostic and therapeutic compromises.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"805-813"},"PeriodicalIF":2.7,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic melanoma in an infant: neoadjuvant radiotherapy and radical neck dissection.","authors":"Niranjan Bista, Patrick Shenjere, Demeesh Oudit","doi":"10.2340/1651-226X.2026.46049","DOIUrl":"10.2340/1651-226X.2026.46049","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"802-804"},"PeriodicalIF":2.7,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Operationalizing fear of cancer recurrence care: a modified Delphi study establishing a consensus-based clinical pathway for Danish cancer survivors.","authors":"Johanne Dam Lyhne, Pernille Bech, Eva Rames Nissen, Christina Maar Andersen, Anne Katrine Hartmann Søby, Brigitta R Villumsen, Henriette Vind Thaysen, Laura Sandholdt Jensen, Iben Husted Nielsen, Thea Otto Mattsson, Anne Johansen, Emma Skov Rahbæk, Ulrike Johansen, Frederik Lynge Overgaard, Lise Ventzel, Lars Henrik Jensen, Matteo Allegretti, Eriseld Krasniqi, Allan 'Ben' Smith, Anders Bonde Jensen","doi":"10.2340/1651-226X.2026.46444","DOIUrl":"10.2340/1651-226X.2026.46444","url":null,"abstract":"<p><strong>Background and purpose: </strong>Fear of cancer recurrence (FCR) is a prevalent concern among cancer survivors. Although evidence-based FCR guidelines exist, their implementation requires further operationalization. This study aimed to establish expert consensus on a clinical pathway to operationalize guideline-concordant FCR care in Denmark. Patient/material and methods: A modified Delphi study was conducted, comprising Round 0 and three Delphi rounds. In Round 1, 112 experts were invited, and 80 participated (71%) in an online survey rating proposed pathway statements. Twenty-seven participants attended a consensus workshop (Round 2) to discuss and refine statements not reaching consensus in Round 1. In Round 3, 71 participants (63%) re-rated the revised statements from Round 2. Consensus was defined as ≥ 80% agreement.</p><p><strong>Results: </strong>Consensus was achieved for 10 statements in Round 1 and 6 revised or newly formulated statements in Round 3, including systematic screening of all cancer survivors with validated tools using a two-step approach, and initiation of screening at transition from treatment to follow-up. Consensus was achieved for need-based assessment guided by symptom severity and patient-expressed need. A matched-care model, aligning treatment intensity with FCR severity, achieved consensus in Round 1. Ongoing monitoring through re-screening during follow-up and post-intervention was endorsed. Timing of assessment and the management of FCR treatment non-response did not reach consensus.</p><p><strong>Interpretation: </strong>This Delphi study provides a consensus-based clinical pathway for FCR, including systematic screening, needs-based assessment, and matched-care allocation. The findings address key implementation gaps in existing FCR guidelines and offer a structured framework for integrating FCR care into routine practice.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"792-801"},"PeriodicalIF":2.7,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exceptional response to alpelisib in a heavily pretreated patient with metastatic breast cancer carrying a PIK3CA mutation outside SOLAR-1 eligible mutations: a case report.","authors":"Karolina F Larsson, Annabelle Forsmark, Henrik Fagman, Maja Drakenberg Danese, Maria Kaire, Matilda Liljedahl, Christoffer Vannas","doi":"10.2340/1651-226X.2026.46486","DOIUrl":"10.2340/1651-226X.2026.46486","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"776-780"},"PeriodicalIF":2.7,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149023603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern Finland.","authors":"Aija Knuuttila, Monica H Ekblom, Lalli O Nurmi, Anna Bonin, Eija K Heikkilä, Maria Silvoniemi","doi":"10.2340/1651-226X.2026.46295","DOIUrl":"10.2340/1651-226X.2026.46295","url":null,"abstract":"<p><strong>Background and purpose: </strong>The aim of the study was to compare overall survival (OS) and time to next treatment (TTNT) of epidermal growth factor receptor (EGFR) mutation positive Non-Small Cell Lung Cancer (NSCLC) patients from start of first therapy, by EGFR mutational sub-type, disease stage at first diagnosis (early vs. advanced stage), first treatment and metastatic sites. Patient/material and methods: This retrospective observational study utilized patient-level data from hospital data lakes at two university hospital districts in Southern Finland on EGFR-mutation-positive NSCLC patients diagnosed between 2017 and 2023. OS and TTNT were analysed from start of first therapy using Kaplan-Meier, multivariable Cox proportional hazard models and log-rank test.</p><p><strong>Results: </strong>Among 544 EGFR-mutant NSCLC patients, 42% had early-stage disease. In early-stage NSCLC, OS did not differ significantly between Del19 and L858R mutations, and surgery was the only initial treatment associated with improved OS, with Del19 providing no additional survival benefit. In advanced-stage NSCLC, L858R mutation was a risk factor for shorter OS compared to Del19 (hazard ratio [HR]: 2.01 95% confidence interval [CI]: 1.34-3.02, p = 0.001). First-line third-generation tyrosine kinase inhibitor (TKI) showed improved OS compared to first-generation TKI (HR: 0.46 95% CI: 0.28-0.78, p = 0.004). Younger patients more often had central nervous system (CNS) and bone metastases. CNS and liver metastases at diagnosis were linked to shorter OS (5.0 and 8.1 months, respectively).</p><p><strong>Interpretation: </strong>EGFR subtype did not affect outcomes in early-stage NSCLC, while Del19 mutations and first-line third-generation TKIs were associated with better outcomes in advanced disease. Younger patients had higher rates of CNS and bone metastases, which were associated with shorter OS.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"781-791"},"PeriodicalIF":2.7,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149023667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in initiating standard first-line cancer treatment and survival for patients with an immigrant background: a Danish register-based cohort study.","authors":"Emma N Ishøy, Maria Kristiansen, Ismail Gögenur, Erik Jakobsen, Lars Lund, Fie Stegenborg, Susanne Rosthøj, Mia K Grand, Pernille Bidstrup, Morten Sodemann, Susanne O Dalton","doi":"10.2340/1651-226X.2026.46256","DOIUrl":"10.2340/1651-226X.2026.46256","url":null,"abstract":"<p><strong>Background and purpose: </strong>Individuals with an immigrant background may face barriers to healthcare. However, evidence on differences in cancer treatment and survival between patients with an immigrant background and patients of Danish origin is limited.</p><p><strong>Patients and methods: </strong>We included patients aged ≥50 years diagnosed with a first primary colon, lung, prostate, or kidney cancer between 2011 and 2022 from national clinical cancer databases. First-line treatment initiation (30/90 days) and survival (1/5 years) were assessed using risk ratios (RRs) comparing patients with an immigrant background to those of Danish origin. Immigrant backgrounds were categorized according to their origin in (1) other Western countries, (2) Central and Eastern Europe, and (3) the Middle East, North Africa, and Central Asia.</p><p><strong>Results: </strong>Overall, there were no systematic differences in the initiation of first-line treatment or survival between patients with an immigrant background and patients of Danish origin. Exceptions included lower probability of initiating treatment (30-day RR: 0.76 [95% confidence interval (CI): 0.62; 0.93] and 90-day RR: 0.92 [95% CI: 0.87; 0.98]) and 1-year risk of death (RR: 0.85 [95% CI: 0.77; 0.93]) among lung cancer patients from Central and Eastern Europe, lower 30-day treatment initiation among patients from the Middle East, North Africa, and Central Asia (RR: 0.80 [95% CI: 0.64; 1.00]), and higher 5-year risk of death among prostate cancer patients from other Western countries (RR: 1.16 [95% CI: 1.01; 1.34]).</p><p><strong>Interpretation: </strong>Overall, patients with an immigrant background had similar initiation of first-line cancer treatment and survival to those of Danish origin, with some statistically significant differences but no consistent pattern across cancer types or regions of origin.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"766-775"},"PeriodicalIF":2.7,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13595832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}